Eleventa finalizes Timapiprant trial enrollment
Eleventa, a portfolio company owned by Maxwell Biotech Venture Fund in association with its development partner Oxagen Ltd., has finalized patient enrollment for its Phase 3 Timapiprant clinical trial. Read More »